A Randomized, Single-dose, Open-label, Single-center, Crossover Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD5718 in Healthy Volunteers
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Atuliflapon (Primary)
- Indications Cardiovascular disorders; Coronary artery disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 24 Mar 2020 Status changed from active, no longer recruiting to completed.
- 21 Feb 2020 Planned End Date changed from 2 Mar 2020 to 21 Feb 2020.
- 21 Feb 2020 Planned primary completion date changed from 2 Mar 2020 to 21 Feb 2020.